Purpose: Software that evaluates the quality of treatment plans (PlanIQᵀᴹ) has become commercially available in recent years. It includes a feasibility assessment tool that provides the ideal dose volume histogram (DVH) for each organ at risk, based on the ideal dose falloff from the prescribed dose at the target boundary. It is important to investigate whether the PlanIQᵀᴹ assessment tool (Feasibility DVHᵀᴹ) can assist treatment planners who are not experienced in treatment planning. Therefore, the present study aimed to evaluate the usefulness of this tool for improving the quality of treatment plans.
Methods: This study included five participants with prostate cancer. Volumetric-modulated arc therapy (VMAT) planning data obtained before and after using the Feasibility DVHᵀᴹ were scored with PlanIQᵀᴹ. The impact of the feasibility assessment tool on the quality of the VMAT plans was evaluated for different patients and treatment planners. The treatment planners include two graduate students, two undergraduate students, and one clinical planner.
Results: Four out of five cases showed improved treatment planning by referring to the Feasibility DVHᵀᴹ. In addition, four of five treatment planners showed improvement in treatment planning by referring to the Feasibility DVHᵀᴹ.
Conclusion: The present findings suggest that referring to the Feasibility DVHᵀᴹ tool may improve the quality of treatment plans for different types of planners and patients. However, planners at any level of experience should be trained to check the dose distribution in addition to checking the DVH.
Funding Support, Disclosures, and Conflict of Interest: Yuji Nakaguchi is employees of TOYO MEDIC CO., LTD.